vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and GREENE COUNTY BANCORP INC (GCBC). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $22.2M, roughly 1.5× GREENE COUNTY BANCORP INC). On growth, GREENE COUNTY BANCORP INC posted the faster year-over-year revenue change (23.8% vs -23.8%). GREENE COUNTY BANCORP INC produced more free cash flow last quarter ($6.2M vs $-47.7M). Over the past eight quarters, GREENE COUNTY BANCORP INC's revenue compounded faster (18.9% CAGR vs -6.2%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Bank of Greene County is an American federally-chartered savings bank headquartered in Catskill, NY. The bank's branches are located in the Upstate New York counties of Greene, Columbia, Albany, Ulster, and Rensselaer.

DNA vs GCBC — Head-to-Head

Bigger by revenue
DNA
DNA
1.5× larger
DNA
$33.4M
$22.2M
GCBC
Growing faster (revenue YoY)
GCBC
GCBC
+47.6% gap
GCBC
23.8%
-23.8%
DNA
More free cash flow
GCBC
GCBC
$53.9M more FCF
GCBC
$6.2M
$-47.7M
DNA
Faster 2-yr revenue CAGR
GCBC
GCBC
Annualised
GCBC
18.9%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
DNA
DNA
GCBC
GCBC
Revenue
$33.4M
$22.2M
Net Profit
$10.3M
Gross Margin
Operating Margin
-211.9%
52.0%
Net Margin
46.3%
Revenue YoY
-23.8%
23.8%
Net Profit YoY
37.4%
EPS (diluted)
$-1.41
$0.60

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
GCBC
GCBC
Q4 25
$33.4M
$22.2M
Q3 25
$38.8M
$21.5M
Q2 25
$49.6M
$20.5M
Q1 25
$48.3M
$20.1M
Q4 24
$43.8M
$17.9M
Q3 24
$89.0M
$16.9M
Q2 24
$56.2M
$16.6M
Q1 24
$37.9M
$15.7M
Net Profit
DNA
DNA
GCBC
GCBC
Q4 25
$10.3M
Q3 25
$-80.8M
$8.9M
Q2 25
$-60.3M
$9.3M
Q1 25
$-91.0M
$8.1M
Q4 24
$7.5M
Q3 24
$-56.4M
$6.3M
Q2 24
$-217.2M
$6.7M
Q1 24
$-165.9M
$5.9M
Operating Margin
DNA
DNA
GCBC
GCBC
Q4 25
-211.9%
52.0%
Q3 25
-231.8%
47.4%
Q2 25
-132.1%
53.5%
Q1 25
-184.1%
44.6%
Q4 24
-236.3%
45.0%
Q3 24
-62.0%
39.6%
Q2 24
-396.7%
41.2%
Q1 24
-469.1%
39.4%
Net Margin
DNA
DNA
GCBC
GCBC
Q4 25
46.3%
Q3 25
-207.9%
41.2%
Q2 25
-121.6%
45.6%
Q1 25
-188.2%
40.1%
Q4 24
41.7%
Q3 24
-63.3%
37.1%
Q2 24
-386.4%
40.6%
Q1 24
-437.3%
37.3%
EPS (diluted)
DNA
DNA
GCBC
GCBC
Q4 25
$-1.41
$0.60
Q3 25
$-1.45
$0.52
Q2 25
$-1.10
$0.55
Q1 25
$-1.68
$0.47
Q4 24
$-1.91
$0.44
Q3 24
$-1.08
$0.37
Q2 24
$-4.23
$0.39
Q1 24
$-3.32
$0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
GCBC
GCBC
Cash + ST InvestmentsLiquidity on hand
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$508.6M
$258.3M
Total Assets
$1.1B
$3.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
GCBC
GCBC
Q4 25
$422.6M
Q3 25
$495.5M
Q2 25
$559.4M
Q1 25
$325.3M
$155.5M
Q4 24
$561.6M
$166.4M
Q3 24
$616.2M
Q2 24
$730.4M
$190.4M
Q1 24
$840.4M
Stockholders' Equity
DNA
DNA
GCBC
GCBC
Q4 25
$508.6M
$258.3M
Q3 25
$559.8M
$248.2M
Q2 25
$613.0M
$238.8M
Q1 25
$647.4M
$229.0M
Q4 24
$716.1M
$218.4M
Q3 24
$797.9M
$216.3M
Q2 24
$833.1M
$206.0M
Q1 24
$987.3M
$199.2M
Total Assets
DNA
DNA
GCBC
GCBC
Q4 25
$1.1B
$3.1B
Q3 25
$1.2B
$3.1B
Q2 25
$1.2B
$3.0B
Q1 25
$1.3B
$3.0B
Q4 24
$1.4B
$3.0B
Q3 24
$1.5B
$2.9B
Q2 24
$1.6B
$2.8B
Q1 24
$1.6B
$2.9B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
GCBC
GCBC
Operating Cash FlowLast quarter
$-47.7M
$6.4M
Free Cash FlowOCF − Capex
$-47.7M
$6.2M
FCF MarginFCF / Revenue
-142.8%
28.0%
Capex IntensityCapex / Revenue
0.0%
0.9%
Cash ConversionOCF / Net Profit
0.62×
TTM Free Cash FlowTrailing 4 quarters
$47.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
GCBC
GCBC
Q4 25
$-47.7M
$6.4M
Q3 25
$-31.6M
$7.0M
Q2 25
$-40.3M
$28.0M
Q1 25
$-51.5M
$7.3M
Q4 24
$-42.4M
$5.3M
Q3 24
$-103.5M
$2.1M
Q2 24
$-84.4M
$24.9M
Q1 24
$-89.3M
$5.6M
Free Cash Flow
DNA
DNA
GCBC
GCBC
Q4 25
$-47.7M
$6.2M
Q3 25
$6.5M
Q2 25
$-40.3M
$27.3M
Q1 25
$-59.1M
$7.3M
Q4 24
$-56.1M
$5.1M
Q3 24
$-118.6M
$2.0M
Q2 24
$-111.4M
$23.4M
Q1 24
$-96.0M
$4.9M
FCF Margin
DNA
DNA
GCBC
GCBC
Q4 25
-142.8%
28.0%
Q3 25
30.4%
Q2 25
-81.2%
133.3%
Q1 25
-122.4%
36.1%
Q4 24
-128.0%
28.6%
Q3 24
-133.2%
11.8%
Q2 24
-198.2%
141.2%
Q1 24
-252.9%
31.3%
Capex Intensity
DNA
DNA
GCBC
GCBC
Q4 25
0.0%
0.9%
Q3 25
0.0%
1.9%
Q2 25
0.1%
3.4%
Q1 25
15.8%
0.3%
Q4 24
31.3%
1.0%
Q3 24
16.9%
0.9%
Q2 24
48.1%
9.1%
Q1 24
17.7%
4.2%
Cash Conversion
DNA
DNA
GCBC
GCBC
Q4 25
0.62×
Q3 25
0.78×
Q2 25
3.00×
Q1 25
0.91×
Q4 24
0.71×
Q3 24
0.34×
Q2 24
3.70×
Q1 24
0.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

GCBC
GCBC

Segment breakdown not available.

Related Comparisons